Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126938871 | 12693887 | 1 | I | 201607 | 20160822 | 20160829 | 20160829 | PER | US-PFIZER INC-2016399580 | PFIZER | 57.00 | YR | F | Y | 80.27000 | KG | 20160829 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126938871 | 12693887 | 1 | PS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 300 MG, UNK | U | 20699 | 300 | MG | PROLONGED-RELEASE CAPSULE | ||||||
126938871 | 12693887 | 2 | SS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 225 MG (150 MG AND 75 MG), 1X/DAY | U | 20699 | 225 | MG | PROLONGED-RELEASE CAPSULE | QD | |||||
126938871 | 12693887 | 3 | SS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 300 MG, UNK | U | 20699 | 300 | MG | PROLONGED-RELEASE CAPSULE |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126938871 | 12693887 | 1 | Depression |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126938871 | 12693887 | Agitation | |
126938871 | 12693887 | Crying | |
126938871 | 12693887 | Intentional product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126938871 | 12693887 | 2 | 201607 | 0 |